Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pfizer
(NY:
PFE
)
29.49
+0.18 (+0.61%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pfizer
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
32
33
Next >
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
January 10, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
January 10, 2022
From
Pfizer Inc.
Via
Business Wire
New Study Explores Whether mRNA Vaccines Could Help Against Cancer
January 05, 2022
Via
Investor Brand Network
Exposures
COVID-19
Watch for Continued Gains in Shares of Pfizer Inc. (PFE)
December 20, 2021
Via
Investor Brand Network
Exposures
COVID-19
Pfizer Inc. (PFE) Climbs to Annual-High Share Price
December 15, 2021
Via
Investor Brand Network
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
January 05, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19
January 04, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 04, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
January 03, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
December 30, 2021
From
Pfizer Inc.
Via
Business Wire
Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts
December 28, 2021
From
Pfizer Inc.
Via
Business Wire
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer's Paxlovid Approval, Tollovir(TM) Phase 2 & COVID Testing
December 23, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
COVID-19
Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment
December 22, 2021
From
Pfizer Inc.
Via
Business Wire
Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
December 22, 2021
From
Pfizer Inc.
Via
Business Wire
Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate
December 20, 2021
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply
December 20, 2021
From
Pfizer Inc.
Via
Business Wire
EMA Issues Advice for Potential Early Use of Pfizer’s Novel COVID-19 Oral Antiviral Candidate
December 16, 2021
From
Pfizer Inc.
Via
Business Wire
U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis
December 14, 2021
From
Pfizer Inc.
Via
Business Wire
Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death
December 14, 2021
From
Pfizer Inc.
Via
Business Wire
Pfizer to Acquire Arena Pharmaceuticals
December 13, 2021
From
Pfizer Inc.
Via
Business Wire
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
December 12, 2021
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Pfizer Declares First-Quarter 2022 Dividend
December 10, 2021
From
Pfizer Inc.
Via
Business Wire
European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis
December 10, 2021
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older
December 09, 2021
From
Pfizer Inc.
Via
Business Wire
Kamoa-Kakula Phase 2 Expansion Now 70% Complete, on Track for Early Start-up in Q2 2022
December 09, 2021
Record copper production in November tops 18,270 tonnes, bringing year-to-date production to more than 87,000 tonnes as at November 30,...
Via
Newsfile
Topics
Emissions
Exposures
COVID-19
Pfizer and BioNTech Provide Update on Omicron Variant
December 08, 2021
From
Pfizer Inc.
Via
Business Wire
Super Generic Drugs Market to See Major Growth by 2027 : Lupin, Apotex, Sanofi, Aurobindo, Dr.Reddy's
December 09, 2021
Get an extensive Super Generic Drugs Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.
Via
SBWire
Topics
Supply Chain
Exposures
Supply Chain
CityHealth Opens Vaccination Program at Las Positas College in Livermore, California
December 07, 2021
Vaccinations and Booster Shots Now Available to Students and Alameda County Residents
Via
Newswire.com
Exposures
COVID-19
Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate
December 07, 2021
From
Pfizer Inc.
Via
Business Wire
Biotech Sector’s Response to Omicron Panic Should be Swift and Effective
December 07, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC – December 7, 2021 – USA News Group – Despite a level of panic that JP Morgan has already downplayed in its 2022 forecasts, the...
Via
FinancialNewsMedia
Exposures
COVID-19
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
32
33
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.